Uterine Cancer
123
23
27
58
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
23 trials with published results (19%)
Research Maturity
58 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
10.6%
13 terminated out of 123 trials
81.7%
-4.8% vs benchmark
5%
6 trials in Phase 3/4
40%
23 of 58 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 58 completed trials
Clinical Trials (123)
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Investigations of Reproductive Cancers in Women
Cancer Loyalty Card Study 2 (CLOCS-2)
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
GYNecologic Cancer-Related COGnitive Impairment
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Sample Collection for Ongoing Research and Product Evaluation Study
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch Syndrome
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer
Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr
Image-Guided Gynecologic Brachytherapy
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer